ArticleNuclear medicine and molecular imaging2021
The Outcome and Safety of Re-challenge Lutetium-177 PSMA (
Article in Nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase Ia study.European journal of nuclear medicine and molecular imaging · 2026Article
- Framework to calculateMedical physics · 2025Article
- Radionuclides Landscape in Prostate Cancer Theranostics.International journal of molecular sciences · 2025Review
- Bone metastases of prostate cancer: Molecular mechanisms, targeted diagnosis and targeted therapy (Review).Oncology reports · 2025Review
- Article
- PSMA radioligand therapy rechallenging: expanding the therapeutic possibilities in metastatic castration resistant prostate cancer.European journal of nuclear medicine and molecular imaging · 2024Article
- Efficacy and safety of rechallenge [European journal of nuclear medicine and molecular imaging · 2024Observational
- Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy.Pharmaceuticals (Basel, Switzerland) · 2024Review
- PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?Theranostics · 2024Article
- Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer-Combination Strategies.Current oncology reports · 2023Review
- Review
- PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (PSMA-RLT) with lutetium-177 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.